Uncategorized

Link to Dr. Gary Kay’s Webinar: “Evaluating Your Compound’s Impact on Driving”

Check out the recording of Dr. Gary Kay’s recent webinar, “Evaluating Your Compound’s Impact on Driving.” (Skip to the three-minute mark for the beginning of the webinar.) In this informative webinar, Cognitive Research Corporation‘s President, Gary Kay, Ph.D., assists you in understanding and implementing FDA requirements for evaluating your compound’s impact on driving. An expert…

Read More

Don’t Let Translations Slow Down Your Trial

  Don’t Let Translations Slow Down Your Trial Accelerate It With Accurate, On-Time Translations Get Your Quote in 24hrs or Less! Rely on a company that understands your study’s cultural and scientific nuances without sacrificing the deadline. No matter your timeline, timezone, or language, NCT Linguistics can provide your team with 100% accurate and on-time…

Read More

2018 Conference Date eCards from the Alliance

As we ring in the new year, we’ve identified some prominent industry conferences in 2018, and added the dates and locations to our annual e-card for your reference. With our Alliance’s growth, we now have a CNS-focused card and a medical version. Both are included below. Alliance principals and partners are presenting at and attending…

Read More

Poster accepted for ISCTM in February

Our Alliance group is proud to announce that one of our sites, Hassman Research Institute (HRI), was recently accepted to present their empirical research poster at the International Society for CNS Clinical Trials and Methodology (ISCTM) Conference on Wednesday, 21 February 2018, 6:00 – 7:30 pm EST. If you are attending ISCTM in 2018, please…

Read More

Congratulations to Sage Therapeutics

Sage Therapeutics Reports Positive Top-line Results from Phase 2 Placebo-Controlled Trial of SAGE-217 in Major Depressive Disorder   – SAGE-217 met primary endpoint and provided rapid, profound and durable effects through 2-week treatment period and additional 4-week follow-up – – Well-tolerated and demonstrated highly statistically significant mean reduction in the HAM-D score compared to placebo…

Read More

NeuroCog Trials Awarded NIH Grant to Study MCI & Alzheimer’s

NeuroCog Trials Awarded NIH Grant to Validate Performance-based Measure of Functioning in MCI & Alzheimer’s Disease Innovative technology answers the call for improved functional capacity measurements in cognitive disorders Durham, North Carolina, October 30, 2017 — NeuroCog Trials, Inc. (NCT), the premiere global cognition and clinical assessment consulting and technology company, today announced it received…

Read More

CNS Network Chosen by Cognitive Research Corporation to Conduct Driving Simulation Crossover Study

GARDEN GROVE, Calif., October 10, 2017 — CNS Network, a leading clinical research center in Southern California, is pleased to announce that the company has been chosen by Cognitive Research Corporation to conduct a driving simulation cross-over study of the sedative effects of a muscle relaxant as compared to a different muscle relaxant and a…

Read More

Dr. Luca Pani Joins NeuroCog Trials

Experienced pharmacologist, clinical scientist and senior regulatory leader brings new capabilities and expertise to growing clinical trials technology and service provider DURHAM, NORTH CAROLINA, September 18, 2017 – NeuroCog Trials (NCT), a clinical technology and research services company dedicated to supporting global drug development, announces the addition of former AIFA Director General, Dr. Luca Pani,…

Read More
Page 1 of 712 »